DOP2016000079A - Glicoproteinas recombinantes y sus usos - Google Patents
Glicoproteinas recombinantes y sus usosInfo
- Publication number
- DOP2016000079A DOP2016000079A DO2016000079A DO2016000079A DOP2016000079A DO P2016000079 A DOP2016000079 A DO P2016000079A DO 2016000079 A DO2016000079 A DO 2016000079A DO 2016000079 A DO2016000079 A DO 2016000079A DO P2016000079 A DOP2016000079 A DO P2016000079A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- recombinant
- galactosidase
- methods
- glycoproteins
- glicoproteins
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 abstract 4
- 108090000288 Glycoproteins Proteins 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70592—CD52
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894879P | 2013-10-23 | 2013-10-23 | |
| US201361901942P | 2013-11-08 | 2013-11-08 | |
| PCT/US2014/061789 WO2015061464A2 (en) | 2013-10-23 | 2014-10-22 | Recombinant glycoproteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000079A true DOP2016000079A (es) | 2016-05-30 |
Family
ID=51871299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000079A DOP2016000079A (es) | 2013-10-23 | 2016-04-11 | Glicoproteinas recombinantes y sus usos |
Country Status (33)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| JP7114485B2 (ja) * | 2016-05-18 | 2022-08-08 | モデルナティエックス インコーポレイテッド | ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド |
| KR102712926B1 (ko) | 2016-10-20 | 2024-10-07 | 상가모 테라퓨틱스, 인코포레이티드 | 파브리병의 치료를 위한 방법 및 조성물 |
| US11357834B2 (en) | 2017-01-10 | 2022-06-14 | Amicus Therapeutics, Inc. | Recombinant α-galactosidase A for treatment of Fabry disease |
| CN113423419A (zh) | 2019-01-04 | 2021-09-21 | 桑格摩生物治疗股份有限公司 | 用于治疗法布里病的方法和组合物 |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5356804A (en) * | 1990-10-24 | 1994-10-18 | Mount Sinai School Of Medicine Of The City Of New York | Cloning and expression of biologically active human α-galactosidase A |
| US6458574B1 (en) * | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| NZ506214A (en) * | 1996-09-13 | 2002-11-26 | Transkaryotic Therapies Inc | Therapy for alpha-galactosidase A deficiency |
| EP1027069B1 (en) | 1997-10-29 | 2006-07-26 | Genzyme Corporation | Gene therapy for gaucher disease |
| US20020081654A1 (en) * | 2000-04-07 | 2002-06-27 | Sandrin Mauro Sergio | Targeting hydrolase enzymes |
| US7138262B1 (en) * | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7133354B2 (en) | 2002-08-26 | 2006-11-07 | Qualcomm Incorporated | Synchronization techniques for a wireless system |
| TWI328614B (en) * | 2002-12-23 | 2010-08-11 | Bristol Myers Squibb Co | Product quality enhancement in mammalian cell culture processes for protein production |
| CN100522988C (zh) * | 2003-04-09 | 2009-08-05 | 诺和诺德公司 | 糖peg化方法及由该方法生产的蛋白质/肽 |
| JP5967861B2 (ja) * | 2007-04-03 | 2016-08-10 | オキシレイン ユーケー リミテッド | 分子のグリコシル化 |
| US20110117601A1 (en) * | 2007-08-31 | 2011-05-19 | Markus Haberger | Glycosylation Profile Analysis |
| US9034341B2 (en) * | 2009-04-20 | 2015-05-19 | Transtech Pharma, Llc | Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions |
| DK2865751T3 (en) * | 2010-03-02 | 2017-01-09 | Protalix Ltd | Stabilized alpha-galactosidase and uses thereof |
| US20120178105A1 (en) | 2011-01-10 | 2012-07-12 | Genzyme Corporation | Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich |
| EP2665814B1 (en) * | 2011-01-20 | 2017-05-17 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
| WO2013055888A2 (en) * | 2011-10-12 | 2013-04-18 | Synageva Biopharma Corp. | Recombinant human naglu protein and uses thereof |
| EP2620506A1 (en) | 2012-01-25 | 2013-07-31 | Arla Foods Amba | Method of producing a galacto-oligosaccharide-containing composition |
| TWI528785B (zh) | 2013-02-08 | 2016-04-01 | 瑞昱半導體股份有限公司 | 立體影像的調整裝置及其方法 |
| AU2014226126B2 (en) | 2013-03-08 | 2019-02-14 | Genzyme Corporation | Continuous purification of therapeutic proteins |
-
2014
- 2014-10-21 TW TW107130267A patent/TWI793159B/zh active
- 2014-10-21 TW TW111139854A patent/TW202332774A/zh unknown
- 2014-10-21 TW TW103136272A patent/TWI642782B/zh active
- 2014-10-22 PL PL14796346T patent/PL3060660T3/pl unknown
- 2014-10-22 MX MX2016005321A patent/MX392532B/es unknown
- 2014-10-22 HR HRP20211197TT patent/HRP20211197T1/hr unknown
- 2014-10-22 EA EA201690826A patent/EA034515B1/ru not_active IP Right Cessation
- 2014-10-22 UA UAA201605455A patent/UA119857C2/uk unknown
- 2014-10-22 EP EP14796346.6A patent/EP3060660B1/en active Active
- 2014-10-22 WO PCT/US2014/061789 patent/WO2015061464A2/en not_active Ceased
- 2014-10-22 MY MYPI2019005029A patent/MY197247A/en unknown
- 2014-10-22 TN TN2016000140A patent/TN2016000140A1/en unknown
- 2014-10-22 SI SI201431857T patent/SI3060660T1/sl unknown
- 2014-10-22 DK DK14796346.6T patent/DK3060660T3/da active
- 2014-10-22 SG SG11201602932WA patent/SG11201602932WA/en unknown
- 2014-10-22 CN CN202110161563.9A patent/CN112852784A/zh active Pending
- 2014-10-22 PE PE2016000543A patent/PE20160723A1/es unknown
- 2014-10-22 CN CN201480070424.3A patent/CN105916984A/zh active Pending
- 2014-10-22 BR BR112016008086A patent/BR112016008086A2/pt not_active Application Discontinuation
- 2014-10-22 CA CA2927852A patent/CA2927852A1/en active Pending
- 2014-10-22 SG SG10201803366PA patent/SG10201803366PA/en unknown
- 2014-10-22 LT LTEPPCT/US2014/061789T patent/LT3060660T/lt unknown
- 2014-10-22 PH PH1/2016/500708A patent/PH12016500708B1/en unknown
- 2014-10-22 EP EP20183936.2A patent/EP3778884A1/en not_active Withdrawn
- 2014-10-22 ES ES14796346T patent/ES2882562T3/es active Active
- 2014-10-22 KR KR1020167013333A patent/KR102298080B1/ko active Active
- 2014-10-22 US US15/030,555 patent/US11208644B2/en active Active
- 2014-10-22 KR KR1020217027690A patent/KR102479886B1/ko active Active
- 2014-10-22 HU HUE14796346A patent/HUE055236T2/hu unknown
- 2014-10-22 JP JP2016526026A patent/JP6837334B2/ja active Active
- 2014-10-22 MY MYPI2016700943A patent/MY178632A/en unknown
- 2014-10-22 NZ NZ720384A patent/NZ720384A/en unknown
- 2014-10-22 CN CN202210146800.9A patent/CN114606217A/zh active Pending
- 2014-10-22 RS RS20210960A patent/RS62171B1/sr unknown
- 2014-10-22 PT PT147963466T patent/PT3060660T/pt unknown
- 2014-10-22 AU AU2014340152A patent/AU2014340152A1/en not_active Abandoned
- 2014-10-23 UY UY0001035794A patent/UY35794A/es not_active Application Discontinuation
-
2016
- 2016-04-11 DO DO2016000079A patent/DOP2016000079A/es unknown
- 2016-04-21 IL IL245255A patent/IL245255B/en active IP Right Grant
- 2016-04-21 CL CL2016000961A patent/CL2016000961A1/es unknown
- 2016-05-17 CR CR20160225A patent/CR20160225A/es unknown
-
2020
- 2020-01-17 JP JP2020005541A patent/JP7296327B2/ja active Active
- 2020-02-11 IL IL272609A patent/IL272609B/en unknown
- 2020-12-21 AU AU2020294173A patent/AU2020294173A1/en not_active Abandoned
-
2021
- 2021-09-22 US US17/482,193 patent/US20220064617A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000022A (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| PE20190563A1 (es) | Genes de mini-distrofina optimizados y casetes de expresion y su uso | |
| MX2016005321A (es) | Glicoproteinas recombinantes y sus usos. | |
| UY37463A (es) | Proteínas de unión | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| CL2018000750A1 (es) | Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih | |
| CO2017009060A2 (es) | Polipéptido hibrido de la enzima de degradación inmunoglobulina g del s. pyogenes y enzima de degradación de inmunoglobulina g del streptococcus equi ssp. zooepidemicus | |
| MX2022006002A (es) | Proteinas de fusion inmunomoduladoras y usos de las mismas. | |
| MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
| MX2017008817A (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| BR112017017886A2 (pt) | gerando populações de células endoteliais arteriais | |
| GT201200252A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| PE20151774A1 (es) | Construcciones de proteinas mitocondriales y sus usos | |
| BR112016000565A2 (pt) | polipeptídeo cíclico, derivado ou análogo do mesmo e seu uso modulador alostérico, composição farmacêutica, processo para produzir a mesma | |
| ES2694667T3 (es) | Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato | |
| MX2018009581A (es) | Inmunoglobulina con fabs en tandem y sus usos. | |
| MX378368B (es) | Receptores de antigeno y usos de los mismos. | |
| BR112016014876A2 (pt) | composto que modula a quantidade ou a atividade de gibspla2, composição farmacêutica, imunógeno que induz uma resposta imune anti-gibspla2, composição de vacina, método para o diagnóstico da imunodeficiência humana associada com a alteração de células t, e, método para a produção de gibspla2 | |
| MX2022002437A (es) | Metodos para la produccion de arginasa humana recombinante 1 y sus usos. | |
| BR112019000837A2 (pt) | células miméticas de célula b | |
| AR095334A1 (es) | Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable | |
| MX392163B (es) | Moduladores de ror gamma. | |
| MX2018007298A (es) | Variantes con mejores propiedades de polipéptidos de fusión relacionados con omega-hidroxilasa. |